Entity

Time filter

Source Type

Ōsaka, Japan

Patent
Sawai Pharmaceutical Co. | Date: 2010-11-08

The present invention provides an atorvastatin-containing coated preparation comprising a solid formulation containing atorvastatin, a pharmacologically acceptable atorvastatin salt, or a solvate thereof coated with a coating agent comprising a polyvinyl alcohol copolymer, a method for inhibiting generation of related substances of atorvastatin, a pharmacologically acceptable atorvastatin salt, or a solvate thereof, comprising coating the solid formulation with a coating agent comprising a polyvinyl alcohol copolymer, and a method for stabilizing atorvastatin, a pharmacologically acceptable atorvastatin salt, or a solvate thereof.


Patent
Sawai Pharmaceutical Co. | Date: 2012-04-10

The present invention provides a pitavastatin-containing preparation containing pitavastatin or a pharmacologically acceptable salt thereof and at least one kind of a basic additive selected from the group consisting of basic magnesium compounds and basic calcium compounds, and an aqueous solution or an aqueous dispersion of the pitavastatin-containing preparation having a pH of more than 8 and 10 or less; and a method for producing a pitavastatin-containing preparation, including blending at least one kind of a basic additive selected from the group consisting of basic magnesium compounds and basic calcium compounds with pitavastatin or a pharmacologically acceptable salt thereof, to make an aqueous solution or an aqueous dispersion of the pitavastatin-containing preparation have a pH of more than 8 and 10 or less.


Patent
Sawai Pharmaceutical Co. | Date: 2015-06-02

A candesartan cilexetil-containing preparation contains candesartan cilexetil and lauromacrogol. The lauromacrogol may be contained at a ratio of 2.4 parts by weight or less with respect to 100 parts by weight of the candesartan cilexetil-containing preparation. The candesartan cilexetil-containing preparation may further contain at least one kind of pharmacologically acceptable additives among a diluent, a disintegrant and a binder.


Patent
Sawai Pharmaceutical Co. | Date: 2015-07-31

Provided is a stable multilayer tablet containing telmisartan and hydrochlorothiazide, in which the decomposition of hydrochlorothiazide during storage, etc., is suppressed. A multilayer tablet comprising a first layer containing telmisartan, meglumine, and a moisture-absorbing substance and a second layer containing hydrochlorothiazide is provided. The moisture-absorbing substance may be a porous moisture-absorbing substance. The porous moisture-absorbing substance may be selected from light anhydrous silicic acid, synthetic aluminum silicate, natural aluminum silicate, calcium silicate, magnesium silicate, magnesium aluminosilicate, magnesium aluminometasilicate, hydrated silicon dioxide, and silicon dioxide.


Patent
Sawai Pharmaceutical Co. | Date: 2015-07-30

The present invention provides a pharmaceutical composition containing candesartan cilexetil, which is produced by wet granulation using a dispersion liquid of candesartan cilexetil together with a powdery additive. The dispersion liquid may also contain a water-soluble polymer, a sugar alcohol, or a stabilizer, and the water-soluble polymer may be hydroxypropylcellulose. The sugar alcohol may be mannitol. In addition, the stabilizer may be lauromacrogol.

Discover hidden collaborations